2023-04-21 13:09:23 ET
Legend Biotech ( NASDAQ: LEGN ) is up ~10% in Friday afternoon trading after releasing abstracts, the results of which were leaked on Tuesday, on its CAR-T therapy Carvykti (ciltacabtagene autoleucel).
The results were accidentally released by the European Hematology Association.
One of the abstracts included results from the phase 3 CARTITUDE-4 trial examining Carvykti, which is also known as cilta-cel, in multiple myeloma patients refractory to Bristol-Myers Squibb's ( BMY ) Revlimid (lenalidomide).
Patients who received cilta-cel had significantly improved overall response rate, rate of complete response and overall minimal residual disease negativity rate compared to those receiving standard of care.
The second abstract was looking at follow-up data from the phase 1b/2 CARTITUDE-1 trial. With a 27.7-month median follow-up, the 27-month rates of progression-free survival and overall survival were, respectively, 55% and 70%.
The final abstract examined the efficacy and safety of LCAR-B38M, another CAR-T therapy, after five years of follow-up. Results showed that median overall response was 55.8 months and 18% of patients were disease free.
Legend ( LEGN ) markets Carvykti with Johnson & Johnson ( NYSE: JNJ ) unit Janssen.
Read why Investing Groups Leader ONeil Trader just upgraded Legend ( LEGN ) to strong buy from buy.
For further details see:
Legend Biotech up 10% on confirming Carvykti multiple myeloma data